AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL) is a Healthcare stock tracked by StreetAlpha. It last closed at $14.82 on Sep 29. ABCL reports earnings on Mon, Nov 9, 2026. The average 12-month price target from 6 analysts is $15.33 (+3.5% from the last close), with a high of $30.00 and a low of $9.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ABCL, 100% of them bullish and 0% bearish. In the past 30 days there were 1 dark pool print totaling $448K, the largest $448K.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on ABCL in the past 90 days. The average target is $15.33, with a high of $30.00 and a low of $9.00, compared with the last close of $14.82.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | JP Morgan | Initiated | Buy | $17 |
| Sep 24 | Goldman Sachs | Reinstated | Hold | $13 |
| Aug 11 | Truist Securities | Maintained | Buy | $30 |
| Aug 6 | Stifel | Maintained | Buy | $9 |
| Aug 6 | Cantor Fitzgerald | Target raised | Buy | $7 → $12 |
Whale Options Flow
90DDark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABCL is in one of them and how their past ABCL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ABCL in an article yet. Here's the latest on the wider market.
For informational purposes only. Not financial advice. Options flow and dark pool data are delayed and may be incomplete.